Downloaded from:
|
|
- Shavonne Allison
- 6 years ago
- Views:
Transcription
1 Robinson, D; Coupland, V; Mller, H (9) n analysis of temporal and generational trends in the incidence of anal and other HPVrelated cancers in Southeast England. ritish journal of cancer, (). pp ISSN 7-9 DOI:.8/sj.bjc Downloaded from: DOI:.8/sj.bjc Usage Guidelines Please refer to usage guidelines at or alternatively contact researchonline@lshtm.ac.uk. vailable under license:
2 ritish Journal of Cancer (9), 57 5 & 9 Cancer Research UK ll rights reserved 7 9/9 $. n analysis of temporal and generational trends in the incidence of anal and other HPV-related cancers in Southeast England D Robinson*,, V Coupland and H Møller Thames Cancer Registry, Division of Cancer Studies, King s College London, st Floor, Capital House, Weston Street, London SE QD, UK Patients diagnosed in 96 4 with cancer of the cervix, anus, vulva, vagina or penis were identified from the Thames Cancer Registry database, and age-standardised period (temporal) incidence rates calculated by direct standardisation. ge-cohort modelling techniques were used to estimate age-specific incidence rates in the earlier and later cohorts, enabling the calculation of agestandardised cohort (generational) rates. Incidence of anal cancer increased for both men and women over the period studied, mainly in those born from 94 onwards. Similar generational patterns were seen for cancers of the vulva and vagina, but those for penile cancer were different. For cervix cancer, the steep downward trend in cohort rates due to screening levelled off in women born from 94 onwards. Our findings are compatible with the hypothesis that changes in sexual practices were a major contributor to the increases of these cancers. Programmes of vaccination against HPV, aimed at reducing the burden of cervical cancer, may also help to reduce the incidence of cancer at other anogenital sites. ritish Journal of Cancer (9), doi:.8/sj.bjc Published online January 9 & 9 Cancer Research UK Keywords: human papillomavirus; anogenital cancers; cohort effects Human papillomavirus (HPV), a sexually transmitted pathogen infecting the anogenital epithelium, is the major cause of cervix cancer. In cervical cancer, HPV infection is the major cause (Schiffman et al, 99; International gency for Research on Cancer, 995; zur Hausen, 996; Walboomers et al, 999; Schlecht et al, ; osch et al, ; Schiffman et al, 7; osch and de Sanjosé, ), and positive associations have been found between HPV infection and cancers of the anus (Daling and Sherman, 99; Frisch et al, 997; Daling et al, 4; jørge et al, ), vulva and vagina (Madeleine et al, 997; Daling et al, ; Goffin et al, 6; Madsen et al, 8). Cancers of the anus, vulva and vagina occur more frequently than expected following cervical intraepithelial neoplasia III or invasive cervical cancer, suggesting a strong common aetiological factor (Evans et al, ). HPV infection may also play a role in a subset of penile squamous cell carcinomas (Iwasawa et al, 99; Rubin et al, ; Daling et al, 5; Heideman et al, 7; Tornesello et al, 8). Increasing trends in anal cancer have been reported, possibly due to changes in sexual practices (Daling et al, 987; Scholefield et al, 99; Frisch et al, 99, 997). If this were the case, a strong generational effect would be expected in the incidence trends of anogenital cancers. We have explored this hypothesis by plotting age-standardised period (temporal) and cohort (generational) rates for cancer sites linked to HPV infection. METHODS Patients diagnosed in 96 4 with cancer of the anus (ICD- code C), vulva (C5), vagina (C5), cervix uteri (C5) or penis *Correspondence: D Robinson; dave.robinson@kcl.ac.uk Received 7 October 8; revised 5 December 8; accepted 8 December 8; published online January 9 (C6) were identified from the Thames Cancer Registry (TCR) database. TCR is a population-based registry, which in this period covered a population of approximately million residents of London and southeast England. ll tumours are coded according to the ICD-O classification (World Health Organization, 976), and were retrospectively recoded to the ICD- classification in the case of tumours diagnosed before its introduction in the early 99s. Examination of proportional frequency plots revealed no coding discrepancies or inconsistencies over the period of the study. ge at diagnosis was categorised into 5-year groups ( 4, 5 9, y, 8 84, 85 þ ), and period of diagnosis into 5-year periods (96 964, , y, 4). Nominal birth cohort groups (875, 88, y, ) were then calculated by subtracting the midpoint of the age group from the midpoint of the period. For each site, an age-standardised incidence rate for each calendar period was calculated by direct standardisation, using the European standard population. s the earlier and later birth cohorts were missing data from the younger and older age groups, respectively, a Poisson regression age-cohort modelling technique (Clayton and Schifflers, 987) was used to estimate the unavailable rates, enabling the estimation of an age-standardised incidence rate for each cohort. s estimates for later cohorts (represented by younger patients diagnosed in recent periods) were based on small numbers of cases, and hence relatively unreliable, we report only estimates for birth cohorts between 885 and 96. RESULTS Table shows the total number of cancers diagnosed over the study period and the incidence by age for each site. Incidence increases with age at all sites, with few cases (other than cervical cancer cases) occurring before age 55.
3 58 Figure shows a modest increase in age-standardised period rates for anal cancer in both men and women. In men, these increased from.79 in to.6 per in 4. In women, the increase was greater, from.45 in to.8 per in 4. In both sexes, rates for consecutive cohorts (Figure ) remained relatively constant (between.5 and. per ) for individuals born between 885 and 95. There was then a sharp increase in rates in the subsequent generations born from 94 onwards. In men, the rates increased from.9 in the 95 cohort to.7 per in the 96 cohort, whereas in women the increase was from.97 in the 95 cohort to 4.8 per in the 96 cohort. Figure and show age-standardised rates, by period and cohort, respectively, for cancers of the vulva and vagina. Period rates have remained fairly constant since the early 99s, whereas cohort rates have increased in recent generations: for vaginal cancer, from.4 in the 94 cohort to.8 per in the 96 cohort; the corresponding rise for vulval cancer was from.65 to.5. For penile cancer, period rates have remained fairly constant, whereas cohort rates have been erratic, with no clear pattern emerging (Figure and ). Figure 4 and show age-standardised period and cohort rates for cervical cancer. Period rates have shown a dramatic decline from.68 in those diagnosed between 985 and 99 to 6.66 per in 4. Cohort rates declined from.7 in the 885 cohort to 7.64 per in the 95 cohort, after which they remained relatively constant. Table summarises these results, showing the age-standardised rates and associated 95% confidence levels. DISCUSSION HPV cancer trends nal cancer incidence in southeast England increased in both men and women over the study period (96 4), by threefold in women and about.5-fold in men; the incidence is now higher in women than in men. Similar trends have been seen in Denmark (Frisch et al, 99), the United States of merica (Melbye et al, 994; Johnson et al, 4) and Sweden (Goldman et al, 989). Increases have also been reported in Scotland (rewster and hatti, 6), where the change in male rates has roughly paralleled that in the female rates from the mid-97s to the mid-99s. Male rates have since plateaued, whereas female rates have continued to rise. In Scotland the female rates were higher than the males rates throughout the period studied, whereas in our population these were initially lower than in men, but became higher from the early 99s onwards. Judson et al (6) found a % increase in invasive vulval cancer in the United States of merica between 97 and. No increase was seen in the period rates for vulval cancer in our data, nor any increase in the period rates for cancers of the vagina or penis. The dramatic decline in rates for cervical cancer from the late 98s onward is similar to that reported in the West Midlands (Clare et al, 8), and reflects the introduction of the National Health Service s screening programme around 988, which has led to the early detection of precancerous cervical lesions and the prevention of many invasive cancers. In our study, in both sexes a marked increase was found in the cohort rates for anal cancer in those born from around 94 onwards. Similar generational patterns were seen for cancers of the vulva and vagina, consistent with a common aetiology. The most likely causes are changes in sexual practice and greater exposure to infectious agents such as HPV. For cancer of the cervix, for which HPV is generally recognised as the major cause, the steep downward trend in cohort rates due to screening levelled off in women born from 94 onwards. We found no clear-cut change in cohort rates for penile cancer, although on average the rates for generations born after 94 were Table Cancer incidence rates per by age at diagnosis ge Cancer site o Total cancers diagnosed nus, males nus, females Vulva Vagina Penis Cervix Rate per Figure Males Females nal cancer. (). () ge-standardised rates by cohort. Rate per ge-standardised rates by cohort Males Females irth cohort ritish Journal of Cancer (9) (), 57 5 & 9 Cancer Research UK
4 HPV cancer trends ge-standardised rates by cohort Rate per.5 Vulva Vagina Rate per.5 Vulva Vagina irth cohort Figure Vulval and vaginal cancers. (). () ge-standardised rates by cohort. ge-standardised rates by cohort Rate per Rate per irth cohort Figure Penile cancer. (). () ge-standardised rates by cohort. higher than in previous cohorts. It may be that the effect of HPV infection is less in penis cancer than in the other cancers, as recently suggested (Tornesello et al, 8). Several studies have linked sexual behaviour with cancer of the anus (Daling et al, 987; Scholefield et al, 99; Frisch et al, 99, 997). In both Denmark (Melbye and iggar, 99) and Scotland (rewster and hatti, 6) a higher prevalence of receptive anal intercourse in women than in men has been reported, and may explain in part the higher incidence of anal cancer in women in these countries. Sexual practices have also been implicated in cancers of the vagina and vulva (Sherman et al, 99; Madsen et al, 8) and of the penis (Maden et al, 99). It should be noted that the cohorts which show the recent increases in incidence are, of necessity, based partially on modelled data, because observational data in the older age groups are not available. However, the variability introduced by the modelling procedure has been included in the calculation of the standard errors of the estimated rates. s can be seen from Table, none of the estimates exhibits excessive variation. The generational patterns seen in the cohort rates presented in this paper, with a marked change from around 94, while not constituting proof, are compatible with the hypothesis that changes in sexual practices are a major contributor to the increases in anogenital cancers other than the cervix. Those born around 94 would have been in their early twenties at the start of the sexual revolution in the early 96s. Peto et al (4) have estimated that cervical cancer screening has prevented an epidemic that would have killed about one in 65 of all ritish women born since 95 and culminated in 6 deaths per year in this country. Trials of vaccination against HPV in teenage girls are currently underway in the United Kingdom. In ustralia, it has been predicted that the public vaccination programme begun in 7 will result in a reduction in the agestandardised incidence of HPV-6 infections of 56% by and 9% by 5 (Smith et al, 8). Programmes of vaccination, aimed at reducing the burden of cervical cancer, may also help to reduce the incidence of cancers of the vulva, vagina and anus in women. & 9 Cancer Research UK ritish Journal of Cancer (9) (), 57 5
5 HPV cancer trends ge-standardised rates by cohort Rate per 5 Rate per irth cohort Figure 4 Cervical cancer. (). () ge-standardised rates by cohort. Table ge-standardised incidence rates (per,) and 95% confidence intervals Site nus, males nus, females Vulva Vagina Penis Cervix Period (.64.9).45 (.6.54). (.9.9).6 (.5.7). (.9.7).74 (..5) (.56.8).5 (.4.59).57 (.4.7).64 (.5.74).89 (.74.4). (.67.7) (.7.).7 (.59.8).9 (.7.8).5 (.4.6).94 (.78.9).74 (.4.4) (.76.5).79 (.67.9).5 (.87.4).46 (.7.55).89 (.74.4).48 (.97.99) (.6.88).75 (.6.87).95 (.77.).5 (.4.6).9 (.77.7).8 (.9.) (.78.98).8 (.7.9).85 (.7.98).58 (.5.66).96 (.85.7).68 (..6) 99.9 (.8.). (.9.).7 (.6.85).54 (.46.6).97 (.87.8) 9.98 (9.65.) (.94.6). (..4).75 (.6.87).5 (.4.57).94 (.84.5) 8.6 ( ).6 (.95.7).8 (.8.9).78 (.65.9).47 (.4.54).9 (.8.) 6.66 ( ) Cohort (.55.77).57 (.5.64).68 (.56.79).79 (.7.88).5 (..).7 (.4.) (.64.87).5 (.45.58). (.9.7).7 (.65.8). (.96.4) 8.65 (8. 9.9) (.84.).58 (.5.65).98 (.84.).6 (.5.67).96 (.8.9) 8.6 ( ) 9.85 (.7.96).55 (.47.6).7 (..).5 (.45.59).84 (.7.96) 5.58 (5. 6.) 95.7 (.6.8).55 (.47.6).4 (.99.9).48 (.4.55).4 (..7) 4.56 ( ) 9.79 (.68.9).59 (.5.67).96 (.8.).5 (.44.6). (.9.5) 5.8 ( ) 95.8 (.69.9).67 (.58.76).9 (.77.7).49 (.4.57).9 (.8.4) 6.9 ( ) 9.79 (.68.9).9 (.8.).64 (.5.78).5 (.4.58).8 (.7.9) 5.9 ( ) (.69.89).4 (.9.6).8 (.67.97).9 (..45).86 (.75.97).95 (.47.4) 9.97 (.85.8).8 (.97.9).64 (.5.78).49 (.4.57).86 (.76.96) 8.8 (8.8 9.) 95.9 (.8.).97 (.87.7).5 (.9.64).5 (.4.57).76 (.67.85) 7.64 (7.6 8.) 94. (..4).9 (.7.).65 (.5.78).4 (.6.49).8 (.7.9) 8.8 ( ) (..6).74 (.59.89).45 (..57).49 (.4.56).8 (.6.4) 8.9 ( ) (.48.8). (..4).7 (.57.86).5 (.45.59).6 (.4.8) 8.7 (8.4 9.) (.59.4).75 (.4.6). (..4).77 (.66.88).95 (.8.7) 9.5 ( ) 96.7 (.44.98) 4.8 ( ).5 (.6.77).8 (.67.96). (.88.8) 7.5 ( ) REFERENCES jørge T, Engeland, Luostarinen T, Mork J, Gislefoss RE, Jellum E, Koskela P, Lehtinen M, Pukkala E, Thoresen SØ, Dillner J () Human papillomavirus infection as a risk factor for anal and perianal skin cancer in a prospective study. r J Cancer 87: 6 64 osch FX, de Sanjosé S () Chapter : Human papillomavirus and cervical cancer burden and assessment of causality. J Natl Cancer Inst Monogr : osch FX, Lorincz, Muñoz N, Meijer CJ, Shah KV () The causal relation between human papillomavirus and cervical cancer. J Clin Pathol 55: rewster D, hatti L (6) Increasing incidence of squamous cell carcinoma of the anus in Scotland, 975. r J Cancer 95: 87 9 Clare J, Edwards D, agnall H, Pearmain P, Lawrence G (8) The use of cervical screening history data to interpret cervical cancer incidence trends. J Public Health : 7 77 Clayton D, Schifflers E (987) Models for temporal variation in cancer rates. I: ge-period and age-cohort models. Stat Med 6: Daling JR, Madeleine MM, Johnson LG, Schwarz SM, Shera K, Wurscher M, Carter JJ, Porter PL, Galloway D, McDougall JK (4) Human papillomavirus, smoking and sexual practices in the etiology of anal cancer. Cancer : 7 8 Daling JR, Madeleine MM, Johnson LG, Schwartz SM, Shera K, Wurscher M, Carter JJ, Porter PL, Galloway D, McDougall JK, Krieger JN (5) Penile cancer: Importance of circumcision, human papillomavirus and smoking in in situ and invasive disease. Int J Cancer 6: Daling JR, Madeleine MM, Schwartz SM, Shera K, Carter JJ, McKnight, Porter PL, Galloway D, McDougall JK, Tamimi H () populationbased study of squamous cell vaginal cancer; HPV and cofactors. Gynecol Oncol 84: 6 7 ritish Journal of Cancer (9) (), 57 5 & 9 Cancer Research UK
6 Daling JR, Sherman KJ (99) Relationship between human papillomavirus infection and tumours of anogenital sites other than the cervix. In The epidemiology of cervical cancer and human papillomaviruses (IRC scientific publication No 9) Muñoz N, osch FX, Shah KV, Meheus (eds), pp 4. Lyon: International gency for Research on Cancer Daling JR, Weiss NS, Hislop TG, Maden C, Coates RJ, Sherman KJ, shley RL, eagrie M, Ryan J, Corey L (987) Sexual practices, sexually transmitted diseases, and the incidence of anal cancer. N Engl J Med 7: Evans HS, Newnham, Hodgson SV, Møller H () Second primary cancers after cervical intraepithelial neoplasia III and invasive cervical cancer in Southeast England. Gynecol Oncol 9: 6 Frisch M, Glimelius, van den rule JC, Wohlfahrt J, Meijer CJLM, Walboomers JMM, Goldman S, Svensson C, dami H-O, Melbye M (997) Sexually transmitted infection as a cause of anal cancer. N Engl J Med 7: 5 58 Frisch M, Melbye M, Møller H (99) Trends in incidence of anal cancer in Denmark. r Med J 6: 49 4 Goffin F, Mayrand M-H, Gauthier P, lobaid, Lussier C, Provencher D, Drouin P, Franco EL, Coutlée F (6) High-risk human papillomavirus infection of the genital tract of women with a previous history or current high-grade vulvar intraepithelial neoplasia. J Med Virol 78: Goldman S, Glimelius, Nilsson, Påhlman L (989) Incidence of anal epidermoid carcinoma in Sweden cta Chir Scand 55: 9 97 Heideman DM, Waterboer T, Pawlita M, Delis-van Diemen P, Nindl I, Leijte J, onfrer JMG, Horenblas S, Meijer CJLM, Snijders PJF (7) Human papillomavirus-6 is the predominant type etiologically involved in penile squamous cell carcinoma. J Clin Oncol 5: International gency for Research on Cancer (995) IRC monographs on the evaluation of carcinogenic risks to humans, Vol. 64. Human papillomaviruses. Lyon: International gency for Research on Cancer Iwasawa, Kumamoto Y, Fujinaga K (99) Detection of human papillomavirus deoxyribonucleic acid in penile carcinoma by polymerase chain reaction and in situ hybridization. J Urol 49: 59 6 Johnson LG, Madeleine MM, Newcomer LM, Schwartz SM, Daling JR (4) nal cancer incidence and survival: the surveillance, epidemiology, and end results experience, 97. Cancer : 8 88 Judson PL, Habermann E, axter NN, Durham S, Virnig (6) Trends in the incidence of invasive and in situ vulvar carcinoma. Obstet Gynecol 7: 8 Madeleine MM, Daling JR, Carter JJ, Wipf GC, Schwartz SM, McKnight, Kurman RJ, eckmann M, Hagensee ME, Galloway D (997) Cofactors with human papillomavirus in a population-based study of vulvar cancer. J Natl Cancer Inst 89: 56 5 Maden C, Sherman KJ, eckmann M, Hislop TG, Te C-Z, shley RL, Daling JR (99) History of circumcision, medical conditions, and sexual activity and risk of penile cancer. J Natl Cancer Inst 85: 9 4 HPV cancer trends Madsen S, Jensen HL, van den rule JC, Wohlfahrt J, Frisch M (8) Risk factors for invasive squamous cell carcinoma of the vulva and vagina population-based case-control study in Denmark. Int J Cancer : Melbye M, iggar RJ (99) Interactions between persons at risk for IDS and the general population in Denmark. m J Epidemiol 5: 59 6 Melbye M, Rabkin C, Frisch M, iggar RJ (994) Changing patterns of anal cancer incidence in the United States, m J Epidemiol 9: Peto J, Gilham C, Fletcher O, Matthews FE (4) The cervical cancer epidemic that screening has prevented in the UK. Lancet 64: Rubin M, Kleter, Zhou M, yala G, Cubilla L, Quint WG, Pirog EC () Detection and typing of human papillomavirus DN in penile carcinoma: evidence for multiple independent pathways of penile carcinogenesis. m J Pathol 59: 8 Schiffman MH, auer HM, Hoover RN, Glass G, Cadell DM, Rush, Scott DR, Sherman ME, Kurman RJ, Wacholder S, Stanton CK, Manos MM (99) Epidemiologic evidence showing that human papillomavirus infection causes most cervical intraepithelial neoplasia. J Natl Cancer Inst 85: Schiffman M, Castle PE, Jeronimo J, Rodriguez C, Wacholder S (7) Human papillomavirus and cervical cancer. Lancet 7: Schlecht NF, Kulaga S, Robitaille J, Ferreira S, Santos M, Miyamura R, Duarte-Franco E, Rohan TE, Ferenczy, Villa LL, Franco EL () Persistent human papillomavirus infection as a predictor of cervical intraepithelial neoplasia. JM 86: 6 4 Scholefield JH, Thornton Jones H, Cuzick J, Northover JM (99) nal cancer and marital status. r J Cancer 6: Sherman KJ, Daling JR, Chu J, Weiss NS, shley RL, Corey L (99) Genital warts, other sexually transmitted diseases, and vulvar cancer. : 57 6 Smith M, Canfell K, rotherton JML, Lew J-, arnabas RV (8) The predicted impact of vaccination on human papillomavirus infections in ustralia. Int J Cancer : Tornesello ML, Duraturo ML, Losito S, otti G, Pilotti S, Stefanon, De Palo G, Gallo, uonaguro L, uonaguro FM (8) Human papillomavirus genotypes and HPV6 variants in penile carcinoma. Int J Cancer : 7 Walboomers JM, Jacobs MV, Manos MM, osch FX, Kummer J, Shah KV, Snijders PJ, Peto J, Meijer CJ, Muñoz N (999) Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. J Pathol 89: 9 World Health Organization (976) International Classification of Diseases for Oncology. Geneva: World Health Organization zur Hausen H (996) Papilloma virus infections a major cause of human cancers. iochim iophys cta 88: F55 F78 5 & 9 Cancer Research UK ritish Journal of Cancer (9) (), 57 5
The Korean Journal of Cytopathology 15 (1) : 17-27, 2004
5 The Korean Journal of Cytopathology 5 () : 7-7, / 5 / / (human papillomavirus, HPV), 6%, 5% HPV. HPV HPV. HPV HPV,,5 HPV HPV. HPV, 6 HPV. HPV HPV International Agency for Research on Cancer (IARC) HPV
More informationPromoting Cervical Screening Information for Health Professionals. Cervical Cancer
Promoting Cervical Screening Information for Health Professionals Cervical Cancer PapScreen Victoria Cancer Council Victoria 1 Rathdowne St Carlton VIC 3053 Telephone: (03) 635 5147 Fax: (03) 9635 5360
More informationThe evolution of HPV-related anogenital cancers reported in Quebec Incidence rates and survival probabilities
The evolution of HPV-related anogenital cancers reported in Quebec Incidence rates and survival probabilities R Louchini, MSc; P Goggin, MD, MSc; M Steben, MD (1) Abstract Non-cervical anogenital cancers
More informationHuman papilloma viruses and cancer in the post-vaccine era
REVIEW 10.1111/j.1469-0691.2009.03032.x Human papilloma viruses and cancer in the post-vaccine era E. Galani and C. Christodoulou Metropolitan Hospital Medical Oncology, Athens, Greece Abstract Human papilloma
More informationHuman papillomaviruses (HPVs) are involved causally in the majority
1464 Human Papillomavirus-Associated Carcinomas in Hawaii and the Mainland U.S. Morten Frisch, M.D., Ph.D. 1,2 Marc T. Goodman, M.P.H., Ph.D. 3 1 Viral Epidemiology Branch, Division of Cancer Epidemiology
More informationFREQUENCY AND RISK FACTORS OF CERVICAL Human papilloma virus INFECTION
Arch. Biol. Sci., Belgrade, 66 (4), 1653-1658, 2014 DOI:10.2298/ABS1404653M FREQUENCY AND RISK FACTORS OF CERVICAL Human papilloma virus INFECTION IN WOMEN IN MONTENEGRO GORDANA MIJOVIĆ 1, TATJANA JOVANOVIĆ
More informationHuman Papillomaviruses and Cancer: Questions and Answers. Key Points. 1. What are human papillomaviruses, and how are they transmitted?
CANCER FACTS N a t i o n a l C a n c e r I n s t i t u t e N a t i o n a l I n s t i t u t e s o f H e a l t h D e p a r t m e n t o f H e a l t h a n d H u m a n S e r v i c e s Human Papillomaviruses
More informationHPV type concordance in sexual couples determines the effect of condoms on regression of flat penile lesions
British Journal of Cancer (2005) 92, 1388 1392 All rights reserved 0007 0920/05 $30.00 www.bjcancer.com HPV type concordance in sexual couples determines the effect of condoms on regression of flat penile
More informationNo HPV High Risk Screening with Genotyping. CPT Code: If Result is NOT DETECTED (x3) If Results is DETECTED (Genotype reported)
CPAL Central Pennsylvania Alliance Laboratory Technical Bulletin No. 117 August 6, 2013 HPV High Risk Screening with Genotyping Contact: Dr. Jeffrey Wisotzkey, 717-851-1422 Director, Molecular Pathology
More information- ii - Rights c
- ii - Rights c - iii - Preface Preface to the third edition Since the first edition of the HPV Information Centre, GLOBOCAN, one of the landmark products of the International Agency for Research on Cancer
More informationTrends in the incidence of human papillomavirus-related noncervical and cervical cancers in Alberta, Canada: a population-based study
Trends in the incidence of human papillomavirus-related noncervical and cervical cancers in Alberta, Canada: a population-based study Lorraine Shack PhD, Harold Y. Lau MD, Longlong Huang MSc, Corinne Doll
More informationUpdate of the role of Human Papillomavirus in Head and Neck Cancer
Update of the role of Human Papillomavirus in Head and Neck Cancer 2013 International & 12 th National Head and Neck Tumour Conference Shanghai, 11 13 Oct 2013 Prof. Paul KS Chan Department of Microbiology
More informationOpinion: Cervical cancer a vaccine preventable disease
Opinion: Cervical cancer a vaccine preventable disease Leon Snyman Principal specialist at the Department of Obstetrics and Gynaecology, Gynaecological Oncology unit, University of Pretoria and Kalafong
More informationRISK OF ANOGENITAL CANCER FOLLOWING DIAGNOSIS OF CERVICAL INTRAEPITHELIAL NEOPLASIA: A PROSPECTIVE POPULATION-BASED STUDY
RISK OF ANOGENITAL CANCER FOLLOWING DIAGNOSIS OF CERVICAL INTRAEPITHELIAL NEOPLASIA: A PROSPECTIVE POPULATION-BASED STUDY Gustaf Edgren BSc Professor Pär Sparén PhD Both at the Department of Medical Epidemiology
More informationThe New England Journal of Medicine SEXUALLY TRANSMITTED INFECTION AS A CAUSE OF ANAL CANCER
SEXUALLY TRANSMITTED INFECTION AS A CAUSE OF AL CANCER MORTEN FRISCH, M.D., PH.D., BENGT GLIMELIUS, M.D., PH.D., ADRIAAN J.C. VAN DEN BRULE, PH.D., JAN WOHLFAHRT, M.SC., CHRIS J.L.M. MEIJER, M.D., PH.D.,
More informationRisk for anogenital cancer and other cancer among women hospitalized with gonorrhea
Acta Obstet Gynecol Scand 2001; 80: 757 761 Copyright C Acta Obstet Gynecol Scand 2001 Printed in Denmark All rights reserved Acta Obstetricia et Gynecologica Scandinavica ISSN 0001-6349 ORIGINAL ARTICLE
More informationHuman Papillomavirus in Squamous Cell Carcinoma of Esophagus in a High-Risk Population
Human Papillomavirus in Esophageal Cancer Tahmasebi Fard Z Department of Molecular Biology, Khatam Postgraduate Faculty, Tehran Farhadi Langroody M Shahrara Medical Laboratory, Tehran Malekzadeh R Digestive
More informationPathology of the Cervix
Pathology of the Cervix Thomas C. Wright Pathology of the Cervix Topics to Consider Burden of cervical cancer 1 Invasive Cervical Cancer Cervical cancer in world Second cause of cancer death in women Leading
More informationThe HPV Vaccination Programme Early intervention in cancer prevention Northern Ireland
The HPV Vaccination Programme Early intervention in cancer prevention Northern Ireland Immunisations Very cost effective intervention Give vaccine before exposure to disease UK has life course approach
More informationand treating joins with the top of canal). at risk for cervical carcinomas, cervix.
CERVICAL CANCER Worldwide, cervical cancer is twelfth most common and the fifth most deadly cancer in women. It affects about 16 per 100,000 women per year and kills about 9 per 100,000 per year. Cervical
More informationCoexisting high-grade glandular and squamous cervical lesions and human papillomavirus infections
British Journal of Cancer (2003) 89, 886 890 All rights reserved 0007 0920/03 $25.00 www.bjcancer.com Coexisting high-grade glandular and squamous cervical lesions and human papillomavirus infections RLM
More informationHPV-Associated Cancers
HPV-Associated Cancers HPV Vaccination Summit: Debunking Myths and Preventing Cancer Thursday, February 2, 2017 St. Luke s Anderson Center Chris Johnson, MPH Cancer Data Registry of Idaho Outline Human
More informationComparison of HPV type distribution in high-grade cervical lesions and cervical cancer: a meta-analysis
British Journal of Cancer (2003) 89, 101 105 All rights reserved 0007 0920/03 $25.00 www.bjcancer.com Short Communication Comparison of HPV type distribution in high-grade cervical lesions and cervical
More informationHPV FREE IDAHO. Fundamentals of HPV Bill Atkinson, MD MPH
HPV FREE IDAHO Fundamentals of HPV Bill Atkinson, MD MPH You are the Key to HPV Cancer Prevention William Atkinson, MD, MPH Associate Director for Immunization Education Immunization Action Coalition February
More informationHuman papiloma virus testing in the cervix of high-risk women: A hospital-based clinicopathological, colposcopic, and cytogenetic study
Research Article Human papiloma virus testing in the cervix of high-risk women: A hospital-based clinicopathological, colposcopic, and cytogenetic study Subhash Bhardwaj 1, Farooq Ahmed Wani 2, Altaf Bandy
More informationSCCPS Scientific Committee Position Paper on HPV Vaccination
SCCPS Scientific Committee Position Paper on HPV Vaccination Adapted from Joint Statement (March 2011) of the: Obstetrical & Gynaecological Society of Singapore (OGSS) Society for Colposcopy and Cervical
More informationINVASIVE OROPHARYNGEAL SQUAMOUS CELL CARCINOMA INCIDENCE RATE* MISSISSIPPI,
HPV-Related Cancers in Mississippi, 2003-2015 The Human Papilloma Virus (HPV) increases the risk of certain types of cancer. A vaccine is available that can prevent the most common cancer-causing types
More informationPrevalence of Human Papillomavirus Genotypes in Routine Pap Smear of 2,562 Korean Women Determined by PCR-DNA Sequencing
Journal of Bacteriology and Virology 2009. Vol. 39, No. 4 p.337 344 DOI 10.4167/jbv.2009.39.4.337 Original Article Prevalence of Human Papillomavirus Genotypes in Routine Pap Smear of 2,562 Korean Women
More informationHPV and Lower Genital Tract Disease. Simon Herrington University of Edinburgh, UK Royal Infirmary of Edinburgh, UK
HPV and Lower Genital Tract Disease Simon Herrington University of Edinburgh, UK Royal Infirmary of Edinburgh, UK Conflict of interest/funding X None Company: Product royalties Paid consultant Research
More informationNorthern Ireland cervical screening programme. Information for primary care and smear takers
Northern Ireland cervical screening programme Information for primary care and smear takers From January 2011, the Northern Ireland cervical screening programme will no longer invite women aged under 25
More informationHUMAN PAPILLOMAVIRUS TESTING
CLINICAL GUIDELINES For use with the UnitedHealthcare Laboratory Benefit Management Program, administered by BeaconLBS HUMAN PAPILLOMAVIRUS TESTING Policy Number: PDS - 016 Effective Date: October 1, 2018
More informationINTRODUCTION HUMAN PAPILLOMAVIRUS
INTRODUCTION HUMAN PAPILLOMAVIRUS Professor Anna-Lise Williamson Institute of Infectious Disease and Molecular Medicine, University of Cape Town National Health Laboratory Service, Groote Schuur Hospital
More informationHPV Epidemiology and Natural History
HPV Epidemiology and Natural History Rachel Winer, PhD, MPH Associate Professor Department of Epidemiology University of Washington School of Public Health rlw@uw.edu Human Papillomavirus (HPV) DNA virus
More informationTime trends in incidence and prevalence of human papillomavirus type 6, 11 and 16 infections in Finland
Journal of General Virology (2003), 84, 2105 2109 DOI 10.1099/vir.0.18995-0 Short Communication Time trends in incidence and prevalence of human papillomavirus type 6, 11 and 16 infections in Finland Päivi
More informationTARGETS To reduce the age-standardised mortality rate from cervical cancer in all New Zealand women to 3.5 per or less by the year 2005.
Cervical Cancer Key points Annually, around 85 women die from, and 230 women are registered with, cervical cancer. The decline in both incidence and mortality rates for cervical cancer has accelerated
More informationWorking Group: This report will be written within the Second Malignancy Working Group.
Title: Human papillomavirus (HPV)-associated malignancies as second cancers in childhood cancer survivors: a report from the Childhood Cancer Survivor Study Working Group: This report will be written within
More informationElevated anal squamous-cell carcinoma risk associated with benign inflammatory anal lesions
Gut Online First, published on November 18, 2005 as 10.1136/gut.2005.070201 Elevated anal squamous-cell carcinoma risk associated with benign inflammatory anal lesions Caroline Nordenvall, 1 Olof Nyrén,
More informationChapter 2: Disease Burden and Cervical Screening in Ontario
Chapter 2: Disease Burden and Cervical Screening in Ontario Learning Objectives On completion of this section, the learner will be able to: 1. Understand human papillomavirus, disease burden, cervical
More informationSIMULTANEOUS SQUAMOUS CELL CARCINOMAS OF THE LOWER FEMALE GENITAL TRACT
SIMULTANEOUS SQUAMOUS CELL CARCINOMAS OF THE LOWER FEMALE GENITAL TRACT Mark H. Stoler, M.D. University of Virginia Health System INTRODUCTION For the average woman the diagnosis of squamous cell carcinoma
More informationValidation of an automated detection platform. for use with the Roche Linear Array HPV Genotyping Test ACCEPTED SEPEHR N.
JCM Accepts, published online ahead of print on September 00 J. Clin. Microbiol. doi:./jcm.0-0 Copyright 00, American Society for Microbiology and/or the Listed Authors/Institutions. All Rights Reserved.
More informationIn February 2007, the National Advisory Committee on
ADULT INFECTIOUS DISEASE NOTES The human papillomavirus vaccine: The promise of cervical cancer prevention BL Johnston MD 1, JM Conly MD 2 In February 2007, the National Advisory Committee on Immunization
More informationAbout anal cancer. Incorporating hospital and community health services, teaching and research
About anal cancer Incorporating hospital and community health services, teaching and research The Homerton Anal Neoplasia Service is a referral centre that provides a screening and treatment service for
More informationA Short Review on Human Papillomavirus Vaccines
A Short Review on Human Papillomavirus Vaccines KF TAM MRCOG HYS NGAN FRCOG Division of Gynaecological Oncology, Department of Obstetrics and Gynaecology, Queen Mary Hospital, The University of Hong Kong,
More informationVIRUS VACCINES & CANCER a story with two chapters
VIRUS VACCINES & CANCER a story with two chapters F X BOSCH Institut Catala d Oncologia Sant Pau 2017 Potential conflict of interest Research and educational institutional grants: GSK, SPMSD, Merck, Qiagen
More informationHPV Infection and associated disease among HIV positive individuals. Admire Chikandiwa. Wits RHI
HPV Infection and associated disease among HIV positive individuals Admire Chikandiwa Wits RHI Outline of presentation Introduction Burden of HPV associated diseases The role of HIV and its interaction
More informationHPV-Associated Disease and Prevention
HPV-Associated Disease and Prevention Odessa Regional Medical Center May 28, 2015 Erich M. Sturgis, MD, MPH Professor Department of Head & Neck Surgery Department of Epidemiology Christopher & Susan Damico
More informationMolecular and Cellular Pathology
British Journal of Cancer (2003) 88, 1095 1100 All rights reserved 0007 0920/03 $25.00 www.bjcancer.com type 16 L1 virus-like particles in sera from patients with genital cancer and patients with carcinomas
More informationHuman Papillomavirus and Related Diseases Report COOK ISLANDS
Human Papillomavirus and Related Diseases Report COOK ISLANDS Version posted at www.hpvcentre.net on 27 July 2017 - ii - Copyright and Permissions ICO/IARC Information Centre on HPV and Cancer (HPV Information
More informationEvidence-Based HPV Disease Prevention HPV VACCINE
Evidence-Based HPV Disease Prevention HPV VACCINE Educating and normalizing vaccine compliance for the teen population Leisha Nolen, MD PhD Enroll in Electronic Poll System In the texting app in your phone:
More informationHPV AND CERVICAL CANCER
HPV AND CERVICAL CANCER DR SANDJONG TIECHOU ISAAC DELON Postgraduate Training in Reproductive Health Research Faculty of Medicine, University of Yaoundé 2007 INTRODUCTION CERVICAL CANCER IS THE SECOND
More informationOPPORTUNISTIC HPV VACCINATION: AN EXPANDED VISION
OPPORTUNISTIC HPV VACCINATION: AN EXPANDED VISION SUMMARY POSITION Human papillomavirus (HPV) infection is preventable but not adequately prevented. At present, Canada has a robust school vaccination program
More informationHPV the silent killer, Prevention and diagnosis
HPV the silent killer, Prevention and diagnosis HPV Human Papilloma Virus is a name given for a silent virus transmitted sexually most of the time, a virus that spreads in the name of love, passion, and
More informationCervical Cancer Screening
Todd R. Jenkins, MD, MSHA Senior Vice Chair Director, Division of Women s Reproductive Healthcare Learning Objectives Describe the etiology, natural history, and usage of the human papillomavirus (HPV)
More informationHPV Prevention: Where Are We and Where Do We Need to Go. Rachel Caskey, MD MAPP
HPV Prevention: Where Are We and Where Do We Need to Go Rachel Caskey, MD MAPP Assistant Professor of Internal Medicine and Pediatrics University of Illinois at Chicago Disclosures I have no financial
More informationHuman papillomavirus and vaccination for cervical cancer
Human papillomavirus and vaccination for cervical cancer Dorothy Machalek Department of Microbiology and Infectious Diseases Royal Women s Hospital, Melbourne, Australia VIRUSES AND CANCER Responsible
More informationHPV vaccination Where are we now? Where are we going? Margaret Stanley Department of Pathology Cambridge
HPV vaccination Where are we now? Where are we going? Margaret Stanley Department of Pathology Cambridge 1 Disclosure Statement Dr. Margaret Stanley has acted as a consultant and advisor for Merck Sharp
More informationThe impact of the HPV vaccine in Scotland.
The impact of the HPV vaccine in Scotland Kevin.pollock@nhs.net Cervical cancer by deprivation Scotland 18 Cancer of the cervix uteri (ICD-10 C53) Age-standardised incidence and mortality rates by SIMD
More informationThe Role of Epidemiologic Studies in Establishing HPV as a Cause of Cancer. April 2, 2008 Margaret M. Madeleine, PhD. Outline
The Role of Epidemiologic Studies in Establishing HPV as a Cause of Cancer April 2, 2008 Margaret M. Madeleine, PhD Outline HPV in Cervical Cancer Basics: Incidence, screening, and the virus Causal criteria
More informationThe devil is in the details
The cobas KNOW THE RISK For cervical cancer prevention The devil is in the details Leading with the cobas as your primary screening method uncovers disease missed by cytology, and can protect women from
More informationScreening for Cervical Cancer. Grand Rounds 1/16/13 Meggan Linck
Screening for Cervical Cancer Grand Rounds 1/16/13 Meggan Linck Cervical Cancer Worldwide 2 nd most common and 5 th deadliest U.S. 8 th most common 80% occur in developing world Median age at diagnosis
More informationRisk of Human Papillomavirus Associated Cancers Among Persons With AIDS
ARTICLE Risk of Human Papillomavirus Associated Cancers Among Persons With AIDS Anil K. Chaturvedi, Margaret M. Madeleine, Robert J. Biggar, Eric A. Engels Background Methods Results Conclusions Although
More informationWho Should and Who Should Not Be Vaccinated Against Human Papillomavirus Infection?
CERVICAL CANCER REVIEW Who Should and Who Should Not Be Vaccinated Against Human Papillomavirus Infection? Jorma Paavonen, MD, Department of Obstetrics and Gynecology, Helsinki University Hospital, Haartmaninkatu
More informationPAP smear. (Papanicolaou Test)
PAP smear (Papanicolaou Test) Is a screening test to prevent/ detect cancerous processes in endocervical canal It reduces the mortality caused by cervical cancer up to 80% M. Arbyn; et al. (2010). "European
More informationVACCINE INTERVENTION ON A COLLEGE CAMPUS TO INCREASE HPV VACCINATION RATES
VACCINE INTERVENTION ON A COLLEGE CAMPUS TO INCREASE HPV VACCINATION RATES Daniel VanDerhoef, BS & Shaida Omid BS, MS Creighton University School of Medicine Disclosures We received grant from the Immunize
More informationEditorial Process: Submission:10/31/2017 Acceptance:09/09/2018
RESEARCH ARTICLE Editorial Process: Submission:10/31/2017 Acceptance:09/09/2018 Evaluation of Anal Cytology in Women with History of Abnormal Pap Smear, Cervical Intraepithelial Neoplasia, Cervical Cancer
More informationEXPOSING DANGERS OF HUMAN PAPILLOMAVIRUS IN BOTH MEN AND WOMEN
EXPOSING DANGERS OF HUMAN PAPILLOMAVIRUS IN BOTH MEN AND WOMEN Aishatu Abdullahi Adamu 3rd Year Student, Department of Medical Laboratory Technology, NIMS University Jaipur (India) ABSTRACT The human papillomavirus
More informationA systematic review of the role of human papilloma virus (HPV) testing within a cervical screening programme: summary and conclusions
British Journal of Cancer (2000) 83(5), 561 565 doi: 10.1054/ bjoc.2000.1375, available online at http://www.idealibrary.com on A systematic review of the role of human papilloma virus (HPV) testing within
More informationHuman Papillomavirus Prevalence and Type Distribution Among 968 Women in South Korea
JOURNAL OF CANCER PREVENTION Vol. 21, No. 2, June 2016 http://crossmark.crossref.org/dialog/?doi=10.15430/jcp.2016.21.2.104&domain=pdf&date_stamp=2016-6-30 http://dx.doi.org/10.15430/jcp.2016.21.2.104
More informationUICC HPV and CERVICAL CANCER CURRICULUM. UICC HPV and Cervical Cancer Curriculum Chapter 5. Application of HPV vaccines Prof. Suzanne Garland MD
UICC HPV and CERVICAL CANCER CURRICULUM 01 Chapter 5. Application of HPV vaccines Director of Microbiological Research Director of Clinical Microbiology and Infectious Diseases The Royal Women's Hospital
More informationQuestions and answers about HPV. Facts about the virus and the vaccine
Questions and answers about HPV Facts about the virus and the vaccine About the introduction of the human papillomavirus (HPV) vaccine Which countries have introduced the HPV vaccine? Over 100 countries
More informationUpdate on HPV Testing. Robert Schlaberg, M.D., Dr. med., M.P.H. Assistant Professor, University of Utah Medical Director, ARUP Laboratories
Update on HPV Testing Robert Schlaberg, M.D., Dr. med., M.P.H. Assistant Professor, University of Utah Medical Director, ARUP Laboratories Disclosures In accordance with ACCME guidelines, any individual
More informationSIGNIFICANCE OF MOLECULAR DIAGNOSTICS IN HUMAN PAPILLOMA VIRUS (HPV) DETERMINATION
Arch. Biol. Sci., Belgrade, 66 (1), 51-56, 2014 DOI:10.2298/ABS1401051K SIGNIFICANCE OF MOLECULAR DIAGNOSTICS IN HUMAN PAPILLOMA VIRUS (HPV) DETERMINATION G. KOVAČEVIĆ 1, V. MILOŠEVIĆ 1, I. HRNJAKOVIĆ-CVJETKOVIĆ
More informationANAL CANCER Updated May 2016 by Dr. Daniel Yokom (PGY-5 Medical Oncology Resident, University of Toronto)
ANAL CANCER Updated May 2016 by Dr. Daniel Yokom (PGY-5 Medical Oncology Resident, University of Toronto) Reviewed by Dr. Lee-Ying (Staff Medical Oncologist, University of Calgary), Dr. Kzyzanowska (Staff
More informationCERVICAL CANCER FACTSHEET. What is cervical cancer?
CERVICAL CANCER FACTSHEET What is cervical cancer? ENGAGe is releasing a series of factsheets to raise awareness of gynaecological cancers and to support its network to work at a grassroots level. Take-up
More informationBiomarkers and HPV testing: The future of cervical screening
THE FUTURE OF CERVICAL SCREENING Earn 3 CPD Points online Biomarkers and HPV testing: The future of cervical screening Professor John O Leary Associate Professor and Director of Pathology Coombe Women
More informationPrevalence of Human papilloma viral infection from women in tertiary care teaching hospital, Tiruchirapalli, India
ISSN: 2319-7706 Volume 3 Number 7 (2014) pp. 713-719 http://www.ijcmas.com Original Research Article Prevalence of Human papilloma viral infection from women in tertiary care teaching hospital, Tiruchirapalli,
More informationHPV-Negative Results in Women Developing Cervical Cancer: Implications for Cervical Screening Options
HPV-Negative Results in Women Developing Cervical Cancer: Implications for Cervical Screening Options R. Marshall Austin MD,PhD Magee-Womens Hospital of University of Pittsburgh Medical Center (UPMC) (raustin@magee.edu)
More informationHuman Papillomavirus
Human Papillomavirus Dawn Palaszewski, MD Assistant Professor of Obstetrics and Gynecology University of February 18, 2018 9:40 am Dawn Palaszewski, MD Assistant Professor Department of Obstetrics and
More informationTrends in HPV-Associated Cancers United States,
National Center for Chronic Disease Prevention and Health Promotion Trends in HPV-Associated Cancers United States, 1999 2014 Elizabeth A. Van Dyne, MD, MPH Division of Cancer Prevention and Control Epidemiology
More informationShrestha P CORRESPONDENCE
NJOG 2015 Jul-Dec; 20 (2):45-49 Original Article Shrestha P 1 2 2 1 Department of Obstetrics and Gynecology, Patan Academy of Health Science, Lalitpur, 2 Department of Obstetrics and Gynecology, Tribhuvan
More informationNHSCSP proposals for cervical screening intervals. Comments and recommendations of Council of the British Society for Clinical Cytology
NHSCSP proposals for cervical screening intervals Comments and recommendations of Council of the British Society for Clinical Cytology The following paper is written on behalf of BSCC Council to express
More informationHPV and the Prevention of Cervical Cancer
HPV and the Prevention of Cervical Cancer Martin C. Mahoney, MD, PhD For a CME/CEU version of this article, please go to http://www.namcp.org/cmeonline.htm, and then click the activity title. Summary Human
More informationGlobal HPV Disease Burden : Rationale for Vaccine
Global HPV Disease Burden : Rationale for Vaccine Muhammet Nabi Kanibir, MD Regional Medical Director Medical Affairs, MSD-Vaccines Muscat, September 2011 HPV Disease Burden Global Regional What do we
More informationShould Anal Pap Smears Be a Standard of Care in HIV Management?
Should Anal Pap Smears Be a Standard of Care in HIV Management? Gordon Dickinson, M.D., FACP Professor of Medicine and Chief Infectious Diseases, Miller School of Medicine Short Answer: NO But 15-20 HPV
More informationHuman papilloma virus vaccination: practical guidelines
International Journal of Research in Medical Sciences Yadav K et al. Int J Res Med Sci. 2014 Nov;2(4):1799-1803 www.msjonline.org pissn 2320-6071 eissn 2320-6012 Brief Report DOI: 10.5455/2320-6012.ijrms201411118
More informationIJC International Journal of Cancer
IJC International Journal of Cancer The risk of cervical cancer associated with specific types of human papillomavirus: a case control study in a UK population Ned G. Powell 1, Sam J. Hibbitts 1, Adam
More informationThe implications of HPV immunisation on cervical screening
The implications of HPV immunisation on cervical screening Dr Maggie Cruickshank Senior Lecturer in Gynaecology Scottish Cervical Cancer Prevention Programme (SCCPP) funded by CSO Cervical screening Detects
More informationWHAT IS CERVICAL CANCER? Presented by Dr. Sylvia Deganus
WHAT IS CERVICAL CANCER? Presented by Dr. Sylvia Deganus The Presentation What is Cancer What and where is the Cervix What causes cervical Cancer How serious is the problem of cervical cancer in Ghana?
More informationTime trends in incidence and prevalence of human papillomavirus type 6, 11 and 16 infections in Finland.
Time trends in incidence and prevalence of human papillomavirus type 6, 11 and 16 infections in Finland. Laukkanen, Päivi; Koskela, Pentti; Pukkala, Eero; Dillner, Joakim; Läärä, Esa; Knekt, Paul; Lehtinen,
More informationThe promise of HPV vaccines for Cervical (and other genital cancer) prevention
The promise of HPV vaccines for Cervical (and other genital cancer) prevention CONTROVERSIES IN OBSTETRICS GYNECOLOGY & INFERTILITY Barcelona March 27 F. Xavier Bosch Catalan Institute of Oncology CURRENT
More informationUtilization of the Biomarkers to Improve Cervical Cancer Screening
Utilization of the Biomarkers to Improve Cervical Cancer Screening Elena BERNAD Victor Babes University of Medicine and Pharmacy Timisoara, Romania Cervical cancer is at the second most common cancer in
More informationHPV- (2014) 16 (9). ISSN
Wakeham, Katie and Kavanagh, Kimberley (2014) The burden of HPVassociated anogenital cancers. Current Oncology Reports, 16 (9). ISSN 1523-3790, http://dx.doi.org/10.1007/s11912-014-0402-4 This version
More informationReal-life challenges in implementing public strategies for HPV vaccination in developing countries, and strategies to increase immunization coverage
Real-life challenges in implementing public strategies for HPV vaccination in developing countries, and strategies to increase immunization coverage Prof. Charbell Miguel Haddad Kury, MD Pediatrician Infectious
More informationThe Global Burden of HPV Related Cancers and Their Prevention
The Global Burden of HPV Related Cancers and Their Prevention What Every Doctor Should Know! Dr. Adrian Lear, MD Conflict of Interest Disclosure I have no financial relations with any commercial entity
More informationHPV/p16 Analyte Control
HPV/p16 Analyte Control Utility review and ring study results Colin Tristram, Director 2017 HPV/p16 Analyte Control Collaboration: Dr Max Robinson at Newcastle University a leading pathologist in head
More informationClinical Performance of Roche COBAS 4800 HPV Test
JCM Accepts, published online ahead of print on 9 April 2014 J. Clin. Microbiol. doi:10.1128/jcm.00883-14 Copyright 2014, American Society for Microbiology. All Rights Reserved. 1 1 2 3 4 5 6 Clinical
More informationAltering Cervical Cancer s Trajectory. Mary S. Beattie, MD, MAS Medical Director, Women s Health BioOncology US Medical Affairs
Altering Cervical Cancer s Trajectory Mary S. Beattie, MD, MAS Medical Director, Women s Health BioOncology US Medical Affairs Objectives and Agenda Objectives: Appreciate cervical cancer (CC) burden Understand
More informationAttitudes to self-sampling of vaginal smear for human papilloma virus analysis among women not attending organized cytological screening
Acta Obstetricia et Gynecologica. 2007; 86: 720 725 ORIGINAL ARTICLE Attitudes to self-sampling of vaginal smear for human papilloma virus analysis among women not attending organized cytological screening
More informationHPV infections and potential outcomes
CONTENTS Preface by Silvia de Sanjosé... 33 Preface by Jacob Bornstein... 37 Author s note... 39 Acknowledgments... 45 CHAPTER 1 HPV infections and potential outcomes HPV: What it is, where it is and what
More informationRecentTrends in Prostate Cancer Incidence and Mortality in Southeast England
European Urology European Urology 43 (2003) 337 341 RecentTrends in Prostate Cancer Incidence and Mortality in Southeast England Helen S. Evans a,*, Henrik Møller a,b a Thames Cancer Registry, Division
More information